Profile of:
Karl Gaffney
Karl Gaffney (MB, BCh, BAO Hons, FRCPI, FRCP) has been a Consultant Rheumatologist in Norwich since 1995 where he is service lead for axial spondyloarthritis and adolescent/transition rheumatology. He is an Honorary Professor at Norwich Medical School, founder member, ex-treasurer and chair of BRITSpA (www.britspa.co.uk), chair of the British Society for Rheumatology (BSR) axial SpA Guidelines Committee, former chair of the medical advisory board, National Axial Spondyloarthritis Society (www.nass.co.uk) and co-lead of the Act on Axial SpA campaign to reduce diagnostic delay (www.actonaxialspa.com) , member of the National Early Inflammatory Arthritis Project Working Group, former associate editor Rheumatology, co-director and founder of the Spondyloarthritis Academy (www.spaacademy.org), and an invited member of the Assessment of Spondyloarthritis International Society www.asas-group.org. He has also represented the BSR and NASS at the National Institute for Health and Care Excellence (NICE) appraisal of biological therapies since 2007. He was Rheumatology Service Director from 2008 until 2016, Director of Postgraduate Education in Norwich between 1999 and 2005, and Director of Rheumatology Training, Eastern Deanery between 2001 and 2007. With NASS he has co-developed primary and secondary care educational programmes for healthcare professionals including Back Pain Seminars, Meeting in a Box, Back in Focus www.axialspabackinfocus.co.uk, Solving Spondyloarthritis www.arma.uk.net/nass-solving-spondyloarthropathy ,RCGP elearning modules, NASS Allies https://nass.co.uk/get-involved/campaign-with-us/nass-allies and Back Pain Plus www.nass.co.uk/back-pain-plus. These initiatives have been awarded national and European awards for excellence in healthcare communication. He is leading the NASS National Gold Standard Delay to Diagnosis project, launched at the House of Commons in July 2020 www.nass.co.uk/get-involved/gold-standard His current research interests include epidemiology, dose optimisation and extra-articular manifestations of axial SpA. He oversees a large clinical trials programme and collaborates with many national and international centres. He has published over 100 papers and has been an invited speaker at national and international meetings
Full name: Karl Gaffney
Current country: United Kingdom
Membership level: Full
Type of membership: Member
Number of publications: 107
Comparative Efficacy of Biologic Disease-Modifying Anti-Rheumatic Drugs for Non-Radiographic Axial Spondyloarthritis: A Systematic Literature Review and Bucher Indirect Comparisons (2023)
https://doi.org/10.1007/s40744-022-00522-0
Real-world evidence for secukinumab in UK patients with psoriatic arthritis or radiographic axial spondyloarthritis: interim 2-year analysis from SERENA (2023)
https://doi.org/10.1093/rap/rkad055
Treatment of axial spondyloarthritis with biologic and targeted synthetic DMARDs: British Society for Rheumatology guideline scope (2023)
https://doi.org/10.1093/rap/rkad039
Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials (2023)
https://doi.org/10.1136/ard-2022-223595
Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: A randomised, double-blind, placebo-controlled, phase 2 study (2023)
https://doi.org/10.1016/s2213-2600(22)00260-0
The PROPER Study; A 48-week, pan-European, real-world study of biosimilar SB5 following transition from reference adalimumab in patients with immune-mediated inflammatory disease (2023)
https://pubmed.ncbi.nlm.nih.gov/37632666/
Diagnostic Delay in axial spodyloarthritis (2023)
https://www.sciencedirect.com/science/article/pii/S1521694223000566?via%3Dihub
Management of biologics in oral surgery (2023)
https://www.jomos.org/articles/mbcb/full_html/2023/03/mbcb230091/mbcb230091.html
Comparative efficacy of biologic disease-modifying anti-rheumatic drugs for non-radiographic axial spondyloarthritis: A systematic literature review and Bucher indirect comparisons (2023)
https://link.springer.com/article/10.1007/s40744-022-00522-0
Miscellaneous Arthropathies (2023)
https://link.springer.com/chapter/10.1007/978-3-031-05002-2_19
Interim 2-year analysis from SERENA: A real-world study in patients with psoriatic arthritis or ankylosing spondylitis treated with secukinumab (2022)
https://doi.org/10.1007/s40744-022-00460-x
Diagnostic delay is common for patients with axial spondyloarthritis: Results from the National Early Inflammatory Arthritis Audit (2022)
https://doi.org/10.1093/rheumatology/keab428
Current evidence on the use of the adalimumab biosimilar SB5 (ImraldiTM): a multidisciplinary perspective (2022)
https://doi.org/10.1080/14712598.2022.2012146
Identifying Axial Spondyloarthritis in Patients With Inflammatory Bowel Disease Using Computed Tomography (2022)
https://doi.org/10.3899/jrheum.220362
Prevalence of undiagnosed axial spondyloarthritis in inflammatory bowel disease patients with chronic back pain: secondary care cross-sectional study (2022)
https://doi.org/10.1093/rheumatology/keac473
Miscellaneous Arthropathies (2022)
https://doi.org/10.1007/978-3-031-05002-2_19
Miscellaneous Arthropathies (2022)
https://doi.org/10.1007/978-3-031-05002-2_19
Inflammatory back pain: a concept, not a diagnosis. (2021)
https://pubmed.ncbi.nlm.nih.gov/33973548/
Delayed diagnosis in axial spondyloarthritis-how can we do better? (2021)
https://pubmed.ncbi.nlm.nih.gov/34244705
The ASAS-OMERACT core domain set for axial spondyloarthritis. (2021)
https://pubmed.ncbi.nlm.nih.gov/34489113/
Current evidence on the use of the adalimumab biosimilar SB5 (ImraldiTM): a multidisciplinary perspective (2021)
https://pubmed.ncbi.nlm.nih.gov/34918591/
Diagnostic delay is common for patients with axial spondyloarthritis: results from the National Early Inflammatory Arthritis Audit (2021)
https://pubmed.ncbi.nlm.nih.gov/33982063/
Feasibility, acceptability and change in health following a telephone-based cognitive behaviour therapy intervention for patients with axial spondyloarthritis. (2021)
https://pubmed.ncbi.nlm.nih.gov/34222775
Masterclass: Axial spondyloarthritis for osteopaths and manual therapists (2021)
https://doi.org/10.1016/j.ijosm.2021.03.005
Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction. (2020)
https://pubmed.ncbi.nlm.nih.gov/32381562
BRITSpA at five (2020)
https://pubmed.ncbi.nlm.nih.gov/31710687
Smoking in spondyloarthritis: unravelling the complexities. (2020)
https://pubmed.ncbi.nlm.nih.gov/32236486
Response to lower dose TNF inhibitors in axial spondyloarthritis; a real-world multicentre observational study (2020)
https://pubmed.ncbi.nlm.nih.gov/32793854
Response to lower dose TNF inhibitors in axial spondyloarthritis; a real-world multicentre observational study (2020)
https://pubmed.ncbi.nlm.nih.gov/32793854
Response to lower dose TNF inhibitors in axial spondyloarthritis; a real-world multicentre observational study (2020)
https://pubmed.ncbi.nlm.nih.gov/32793854
Response to lower dose TNF inhibitors in axial spondyloarthritis; a real-world multicentre observational study (2020)
https://pubmed.ncbi.nlm.nih.gov/32793854
Induction of Sustained Clinical Remission in Early Axial Spondyloarthritis Following Certolizumab Pegol Treatment: 48-Week Outcomes from C-OPTIMISE (2020)
https://pubmed.ncbi.nlm.nih.gov/32529495
Predictors of extra-articular manifestations in axial spondyloarthritis and their influence on TNF-inhibitor prescribing patterns: results from the British Society for Rheumatology Biologics Register in Ankylosing Spondylitis. (2020)
https://pubmed.ncbi.nlm.nih.gov/32641447
Secukinumab Use in Patients with Moderate to Severe Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis in Real-World Setting in Europe: Baseline Data from SERENA Study. (2020)
https://pubmed.ncbi.nlm.nih.gov/32378070
Feasibility, acceptability and change in health following a telephone-based cognitive behaviour therapy intervention for patients with axial spondyloarthritis. (2020)
https://pubmed.ncbi.nlm.nih.gov/34222775
Severe colitis complicating secukinumab (Cosentyx® ) therapy. (2019)
https://pubmed.ncbi.nlm.nih.gov/31854471
